Literature DB >> 10757191

Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function.

M L Glover1, E Cole, J Wolfsdorf.   

Abstract

PURPOSE: The purpose of this study was to determine a vancomycin dosage regimen among pediatric intensive care unit (PICU) patients with normal renal function resulting in desired peak and trough serum concentration and to determine the predictability of vancomycin peak concentrations based on reported trough concentrations.
MATERIALS AND METHODS: The medical records of all PICU patients who received vancomycin over a 12-month period were identified through a hospital computer search and were obtained from the hospital's Department of Medical Records. Demographic and laboratory data as well as the patient's vancomycin dosing history were recorded. Patients who lacked appropriately timed vancomycin peak and trough concentrations or who exhibited renal dysfunction were excluded from the study population. The optimal vancomycin dose and the predictability of peak concentrations based on trough concentrations were assessed.
RESULTS: A total of 135 patients were identified as having received vancomycin therapy during their PICU hospitalization between June 1997 and June 1998. Fifty-nine patients were excluded due to renal dysfunction or inappropriate vancomycin concentrations resulting in 76 patients representing our study population. The initial mean dose of vancomycin was 47 mg/kg/day resulting in a mean peak and trough serum concentration of 19 and 6 microg/mL, respectively. A mean of 2.2 (range, 1 to 5) and 2.1 (range, 1 to 5) peak and trough serum concentrations were reported for each patient, respectively. A mean of 1.1 (range, 0 to 4) dosing changes per patient was noted resulting in a final mean dose of 60 mg/kg/day corresponding to a mean peak and trough serum concentration of 26 and 8 microg/mL, respectively. A vancomycin trough concentration >5 microg/mL was highly predictive for a corresponding peak concentration >20 microg/mL (P > .0001). Eighty percent of the trough concentrations <5 microg/mL were associated with peak concentrations <20 microg/mL, whereas 81% of trough concentrations >5 microg/mL were associated with corresponding peak concentrations >20 microg/mL.
CONCLUSIONS: PICU patients required higher doses of vancomycin than are typically prescribed to achieve conventionally accepted peak and trough vancomycin serum concentrations. In the absence of renal impairment, we recommend an initial dosage regimen of 60 mg/kg/day divided every 8 hours. Vancomycin trough concentrations are highly predictive of corresponding peak concentrations and therefore may negate the need to obtain routine peak concentrations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757191     DOI: 10.1053/jcrc.2000.0150001

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  18 in total

Review 1.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Authors:  Geisa Cristina da Silva Alves; Samuel Dutra da Silva; Virginia Paula Frade; Danielle Rodrigues; André de Oliveira Baldoni; Whocely Victor de Castro; Cristina Sanches
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

2.  Pediatric pharmacokinetics of vancomycin: a canadian perspective.

Authors:  Anais Delicourt; Jean-François Bussières; Denis Lebel
Journal:  Can J Hosp Pharm       Date:  2011-03

Review 3.  Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin.

Authors:  Roopali Sharma; Margaret R Hammerschlag
Journal:  Curr Infect Dis Rep       Date:  2019-09-05       Impact factor: 3.725

4.  Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review.

Authors:  Kim W Benner; Mary A Worthington; David W Kimberlin; Kim Hill; Kevin Buckley; Nancy M Tofil
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

5.  Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.

Authors:  Adam Frymoyer; Adam L Hersh; Zlatan Coralic; Leslie Z Benet; B Joseph Guglielmo
Journal:  Clin Ther       Date:  2010-03       Impact factor: 3.393

6.  Achieving therapeutic vancomycin levels in pediatric patients.

Authors:  Jenny Hoang; Deonne Dersch-Mills; Lauren Bresee; Timothy Kraft; Otto G Vanderkooi
Journal:  Can J Hosp Pharm       Date:  2014-11

7.  Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care Hospital.

Authors:  Kannan Sridharan; Amal Al-Daylami; Reema Ajjawi; Husain Am Al Ajooz
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.022

8.  Use of Individual Pharmacokinetics to Improve Time to Therapeutic Vancomycin Trough in Pediatric Oncology Patients.

Authors:  Calvin L Miller; S Alexander Winans; John J Veillette; Steven C Forland
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

9.  Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.

Authors:  Adam Frymoyer; Adam L Hersh; Leslie Z Benet; B Joseph Guglielmo
Journal:  Pediatr Infect Dis J       Date:  2009-05       Impact factor: 2.129

10.  Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients.

Authors:  Dae Il Kim; Mi Sun Im; Jin Hyoung Choi; Jina Lee; Eun Hwa Choi; Hoan Jong Lee
Journal:  Korean J Pediatr       Date:  2010-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.